TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01569503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation (VNS)
Description: VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
Study: NCT00775983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laminaria
Description: place device in cervix for dilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Description: Place in cervix for dilation.
Study: NCT01843907

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empowerment
Description: To give patients the necessary resources to take care of their own health

Intervention type: OTHER
Group type: OTHER
Intervention: Conversation with nurse
Description: To find out, if the nurse, using her ....
Study: NCT04315012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: receive mobile app-based education
Description: to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
Study: NCT02154113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrashape
Description: All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Velashape II
Description: All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
Study: NCT02362854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional peri-implantitis treatment
Description: Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DL application in peri-implantitis
Description: Diode laser application in the diseased implants.
Study: NCT01947556

Intervention type: DRUG
Group type: OTHER
Intervention: insulin aspart
Description: After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.

Intervention type: DRUG
Group type: OTHER
Intervention: insulin aspart
Description: After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
Study: NCT01074021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus chemoradiotherapy
Description: Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)
Study: NCT02291107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat (Hocoma, Zurich, Switzerland)
Description: Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
Study: NCT04336267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) group
Description: Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
Study: NCT00708630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended information on side effects
Description: More detailed information on possible side effects of vaccine
Study: NCT03413527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS Treatment
Study: NCT01398592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50mg vildagliptin bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg sitagliptin po qd
Study: NCT01604382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: General Anesthesia as described above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neuraxial anesthesia
Description: Neuraxial anesthesia as described above
Study: NCT03769181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01585233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT01239147

Intervention type: OTHER
Group type: OTHER
Intervention: Diet rich in whole grain
Description: Ready-to-eat breakfast cereals and other cereal products, rich in whole grain

Intervention type: OTHER
Group type: OTHER
Intervention: Refined grain
Description: Ready-to-eat breakfast cereals and other cereal products, low in whole grain
Study: NCT04050800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon 11 Butanol
Description: Two sequential administrations of a PET tracer
Study: NCT02431403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESHAP-Imatinib
Description: After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESHAP-Imatinib
Description: After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESHAP-Imatinib
Description: After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESHAP-Imatinib
Description: After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
Study: NCT04534192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JADE Balloon
Description: Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
Study: NCT00787566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal granisetron
Description: 0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal granisetron
Description: 0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal granisetron
Description: 0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
Study: NCT04485286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
Study: NCT04726917

Intervention type: BEHAVIORAL
Intervention: Pulmonary rehabilitation
Description: Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
Study: NCT04496089

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab
Description: A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
Study: NCT03734679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurVeil Drug Coated Balloon
Description: Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
Study: NCT06064981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message nudges
Description: Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment contract
Description: In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone.
Study: NCT04057755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT02531828

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of dressings for surgical correction.
Description: Dressing for surgical correction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POLYSHAFT®
Study: NCT06156969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training
Description: Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes.
Study: NCT04467333

Intervention type: OTHER
Intervention: All lung cancer patients.
Description: There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
Study: NCT00718965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: one tablet in the evening with dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: one tablet in the evening with dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet in the evening with dinner
Study: NCT01484990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa
Description: Intestinal Gel
Study: NCT03676374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg taken once a day as add-on to PPI (2x/d)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet taken once a day as add-on to PPI (2x/d)
Study: NCT00936975

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Sodium Fluoride
Description: Undergo fluorine F 18 sodium fluoride PET scan
Study: NCT03652961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
Study: NCT04256993

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.

Intervention type: DRUG
Intervention: Other standard care
Description: Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
Study: NCT03706677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon (Arctic Front Advance Cryoballoon)
Description: Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Catheter (ThermoCool Smarttouch)
Description: Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
Study: NCT01557270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: ropivacaine + saline placebo, single shot perineural application
Study: NCT00990561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate ointment twice daily + LacHydrin lotion twice daily
Description: Topical corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate ointment once daily + LacHydrin lotion twice daily
Description: Topical corticosteroid
Study: NCT00395083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Self-management Education
Description: The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
Study: NCT04204486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Functional strength training, 1 hour, 3 times a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Functional strength training, 1 hour, 3 times a week.
Study: NCT04305223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity stretching program
Description: A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
Study: NCT02600806

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml

Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin
Description: Patients are given oral levofloxacin when procalcitonin levels are \>= 0.5 ng/ml.
Study: NCT06024863

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening stress test on a bicycle ergometer (usual practise)
Study: NCT03111147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0 degrees humeral component version
Description: RTSA with humeral component positioned in 0 degrees of version

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 degrees humeral component retroversion
Description: RTSA with humeral component positioned in 30 degrees of retroversion
Study: NCT00345683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)
Description: Booster dose by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB
Description: Booster dose by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Booster dose by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Booster dose by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: Single dose by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: Single dose by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Single dose by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Single dose by subcutaneous injection
Study: NCT01893866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 x 30 mg/mL pegvisomant
Description: Subcutaneous injection, 30 mg, single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 15 mg/mL pegvisomant
Description: Subcutaneous injection, 2 injections of 15 mg, single dose.
Study: NCT03805178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20mg/m2 Plasmapheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20mg/m2 Plasmapheresis
Study: NCT03256513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model controlling
Description: control blood pressure by statistical l model with anticipate lowest peri-procedure risk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional controlling
Description: control blood pressure by conventional strategy
Study: NCT01796431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eviplera®